{"id":"nivolumab-relatlimab-fdc","safety":{"commonSideEffects":[{"rate":null,"effect":"Fatigue"},{"rate":null,"effect":"Diarrhea"},{"rate":null,"effect":"Rash"},{"rate":null,"effect":"Immune-mediated colitis"},{"rate":null,"effect":"Immune-mediated pneumonitis"},{"rate":null,"effect":"Hepatotoxicity"}]},"_chembl":{"chemblId":"CHEMBL2108738","moleculeType":"Antibody"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Nivolumab is a PD-1 inhibitor that prevents tumor cells from suppressing T-cell activity via the PD-1/PD-L1 axis. Relatlimab is a LAG-3 inhibitor that blocks a second immune checkpoint, further enhancing T-cell activation and proliferation. Together, the combination provides dual checkpoint inhibition to overcome multiple immune evasion mechanisms used by tumors.","oneSentence":"This fixed-dose combination blocks both PD-1 and LAG-3 checkpoints on immune cells, releasing dual brakes on anti-tumor immunity.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:50:25.803Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Melanoma (advanced or metastatic)"},{"name":"Non-small cell lung cancer"}]},"trialDetails":[{"nctId":"NCT06325683","phase":"PHASE2","title":"Anti-Lag-3 (Relatlimab) and Anti-PD-1 Blockade (Nivolumab) Versus Standard of Care (Lomustine) for the Treatment of Patients With Recurrent Glioblastoma","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2024-11-08","conditions":"Progressive Glioblastoma, Recurrent Glioblastoma","enrollment":184},{"nctId":"NCT02465060","phase":"PHASE2","title":"Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2015-08-17","conditions":"Advanced Lymphoma, Advanced Malignant Solid Neoplasm, Bladder Carcinoma","enrollment":6452},{"nctId":"NCT07492680","phase":"PHASE2","title":"A Study of BMS-986504 Monotherapy and in Combination With Other Agents in Participants With Advanced and/or Metastatic Solid Tumors With Homozygous MTAP Deletion (MountainTAP-5)","status":"NOT_YET_RECRUITING","sponsor":"Bristol-Myers Squibb","startDate":"2026-07-17","conditions":"Solid Tumors","enrollment":260},{"nctId":"NCT07281924","phase":"PHASE1, PHASE2","title":"Hepzato Kit and Opdualag for Metastatic Melanoma and Liver Metastasis","status":"RECRUITING","sponsor":"University of Wisconsin, Madison","startDate":"2026-04","conditions":"Metastatic Melanoma, Liver Metastases","enrollment":15},{"nctId":"NCT03044613","phase":"PHASE1","title":"Nivolumab +/- Relatlimab Prior to Chemoradiation With II/III Gastro/Esophageal Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins","startDate":"2017-07-11","conditions":"Gastric Cancer, Esophageal Cancer, GastroEsophageal Cancer","enrollment":32},{"nctId":"NCT03607890","phase":"PHASE2","title":"Study of Nivolumab and Relatlimab in Advanced Mismatch Repair Deficient Cancers Resistant to Prior PD-(L)1 Inhibitor","status":"ACTIVE_NOT_RECRUITING","sponsor":"Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins","startDate":"2018-11-16","conditions":"Refractory MSI - H Solid Tumors Prior of PD-(L) 1 Therapy, MSI-H Tumors","enrollment":38},{"nctId":"NCT06708949","phase":"PHASE2","title":"A Randomized Phase 2 Trial of Nivolumab, Relatlimab Plus Ipilimumab vs. Nivolumab Plus Ipilimumab in First-line Advanced Renal Cell Carcinoma (RCC)","status":"RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2025-03-20","conditions":"Renal Cell Carcinoma, Clear Cell","enrollment":15},{"nctId":"NCT06264180","phase":"PHASE3","title":"VO and Nivolumab vs Physician's Choice in Advanced Melanoma That Progressed on Anti-PD-1 & Anti-CTLA-4 Drugs [IGNYTE-3]","status":"RECRUITING","sponsor":"Replimune Inc.","startDate":"2024-07-11","conditions":"Advanced Melanoma","enrollment":400},{"nctId":"NCT07459543","phase":"PHASE4","title":"A Study To Assess the Safety, and Tolerability of Nivolumab + Relatlimab Fixed-Dose Combination (FDC) In Untreated, Unresectable or Metastatic Melanoma Participants In India","status":"NOT_YET_RECRUITING","sponsor":"Bristol-Myers Squibb","startDate":"2026-11-15","conditions":"Untreated Melanoma, Unresectable Melanoma, Metastatic Melanoma","enrollment":30},{"nctId":"NCT03026140","phase":"PHASE2","title":"Neoadjuvant Immune Checkpoint Inhibition and Novel IO Combinations in Early-stage Colon Cancer","status":"RECRUITING","sponsor":"The Netherlands Cancer Institute","startDate":"2017-03-29","conditions":"Colon Carcinoma","enrollment":353},{"nctId":"NCT06246916","phase":"PHASE3","title":"A Study With Combinations of Anti-LAG-3 and Anti-PD-1 Antibodies in Adult Participants With Advanced or Metastatic Melanoma (Harmony Head-to-Head)","status":"RECRUITING","sponsor":"Regeneron Pharmaceuticals","startDate":"2024-09-09","conditions":"Melanoma","enrollment":560},{"nctId":"NCT06963905","phase":"PHASE1, PHASE2","title":"Saci Nivo Rela for TNBC","status":"RECRUITING","sponsor":"Yale University","startDate":"2025-12-29","conditions":"Metastatic Triple-negative Breast Cancer","enrollment":60},{"nctId":"NCT05912244","phase":"PHASE2","title":"A Study of IO102/IO103, Nivolumab, and Relatlimab in People With Melanoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2023-06-09","conditions":"Melanoma","enrollment":43},{"nctId":"NCT06151236","phase":"PHASE2","title":"Neoadjuvant Nivolumab and Relatlimab in Merkel Cell Carcinoma","status":"RECRUITING","sponsor":"Melanoma Institute Australia","startDate":"2024-03-11","conditions":"Merkel Cell Carcinoma","enrollment":20},{"nctId":"NCT04080804","phase":"PHASE2","title":"Study of Safety and Tolerability of Nivolumab Treatment Alone or in Combination With Relatlimab or Ipilimumab in Head and Neck Cancer","status":"RECRUITING","sponsor":"Dan Zandberg","startDate":"2019-12-20","conditions":"Head and Neck Squamous Cell Carcinoma (HNSCC)","enrollment":80},{"nctId":"NCT05418972","phase":"PHASE2","title":"A Phase 2 Clinical Trial of Neoadjuvant Relatlimab and Nivolumab in High Risk, Clinical Stage II Cutaneous Melanoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Melanoma Institute Australia","startDate":"2023-08-14","conditions":"Stage II Melanoma","enrollment":20},{"nctId":"NCT05704647","phase":"PHASE2","title":"Phase II Study of Nivolumab in Combination With Relatlimab in Patients With Active Melanoma Brain Metastases","status":"RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2023-02-23","conditions":"Melanoma (Skin)","enrollment":30},{"nctId":"NCT05034536","phase":"PHASE2","title":"PD-1 Antibody Therapy + Infliximab for Metastatic Melanoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Massachusetts General Hospital","startDate":"2022-02-07","conditions":"Metastatic Melanoma","enrollment":36},{"nctId":"NCT04326257","phase":"PHASE2","title":"Personalized Immunotherapy in Patients With Recurrent /Metastatic SCCHN That Have Progressed on Prior Immunotherapy","status":"COMPLETED","sponsor":"Dan Zandberg","startDate":"2020-05-14","conditions":"Squamous Cell Carcinoma of the Head and Neck","enrollment":20},{"nctId":"NCT06295159","phase":"PHASE2","title":"Neoadjuvant and Adjuvant Anti-PD1 or Combinations for Locoregionally Advanced Melanoma","status":"RECRUITING","sponsor":"H. Lee Moffitt Cancer Center and Research Institute","startDate":"2024-05-17","conditions":"Melanoma Stage III, Melanoma Stage IV, Advanced Melanoma","enrollment":90},{"nctId":"NCT01968109","phase":"PHASE1, PHASE2","title":"An Investigational Immuno-therapy Study to Assess the Safety, Tolerability and Effectiveness of Anti-LAG-3 With and Without Anti-PD-1 in the Treatment of Solid Tumors","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2013-11-05","conditions":"Neoplasms by Site","enrollment":1482},{"nctId":"NCT05428007","phase":"PHASE2","title":"Interleukin-6 Receptor Inhibitor Sarilumab in Combination With Ipilimumab, Nivolumab and Relatlimab in Patients With Unresectable Stage III or Stage IV Melanoma","status":"RECRUITING","sponsor":"NYU Langone Health","startDate":"2023-02-02","conditions":"Melanoma, Unresectable Melanoma","enrollment":105},{"nctId":"NCT03610711","phase":"PHASE1, PHASE2","title":"REACTION (Radiation Enhanced Assessment of Combination Therapies in Immuno-ONcology) - Nivolumab or Nivolumab in Combination With Other Immuno-oncology (IO) Agents After Targeted Systemic Radiation in Patients With Advanced Esophagogastric Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins","startDate":"2019-03-06","conditions":"Gastroesophageal Cancer, Immune Checkpoint Inhibition","enrollment":21},{"nctId":"NCT04658147","phase":"PHASE1","title":"Feasibility and Efficacy of Perioperative Nivolumab With or Without Relatlimab for Patients With Potentially Resectable Hepatocellular Carcinoma (HCC)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins","startDate":"2021-05-28","conditions":"Hepatocellular Carcinoma","enrollment":31},{"nctId":"NCT06288191","phase":"PHASE2","title":"Neoadjuvant Nivolumab and Relatlimab in Cutaneous Squamous Cell Carcinoma","status":"RECRUITING","sponsor":"Melanoma Institute Australia","startDate":"2024-06-21","conditions":"Cutaneous Squamous Cell Carcinoma","enrollment":20},{"nctId":"NCT05134948","phase":"PHASE1, PHASE2","title":"A Study to Assess Relatlimab and Nivolumab Fixed-dose Combination in Chinese Participants With Advanced Solid Tumors","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2021-11-30","conditions":"Advanced Solid Tumors","enrollment":24},{"nctId":"NCT04866810","phase":"NA","title":"The Effect of Diet and Exercise on ImmuNotherapy and the Microbiome (EDEN)","status":"SUSPENDED","sponsor":"National Cancer Institute (NCI)","startDate":"2023-07-25","conditions":"Melanoma","enrollment":24},{"nctId":"NCT05704933","phase":"EARLY_PHASE1","title":"Pilot Study of Nivolumab w/Ipilimumab or Relatlimab in Surgically Resectable Melanoma Brain Metastases","status":"COMPLETED","sponsor":"H. Lee Moffitt Cancer Center and Research Institute","startDate":"2023-06-06","conditions":"Metastatic Melanoma, Metastasis to Brain","enrollment":1},{"nctId":"NCT05148546","phase":"PHASE2","title":"Neoadjuvant Study With Combination Immuno-oncology for Primary Clear Cell Renal Cell Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"The Netherlands Cancer Institute","startDate":"2022-04-28","conditions":"Renal Cell Carcinoma","enrollment":69},{"nctId":"NCT06712927","phase":"PHASE2","title":"Trial of Relatlimab, Nivolumab, and Ipilimumab in Patients With Asymptomatic and Symptomatic Melanoma Brain Metastases","status":"RECRUITING","sponsor":"Stanford University","startDate":"2025-08-06","conditions":"Melanoma, Brain Metastases","enrollment":60},{"nctId":"NCT05625399","phase":"PHASE3","title":"A Study of Subcutaneous Nivolumab + Relatlimab Fixed-dose Combination (FDC) in Previously Untreated Metastatic or Unresectable Melanoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Bristol-Myers Squibb","startDate":"2023-03-06","conditions":"Melanoma","enrollment":579},{"nctId":"NCT05328908","phase":"PHASE3","title":"A Study of Nivolumab-relatlimab Fixed-dose Combination Versus Regorafenib or TAS-102 in Participants With Later-lines of Metastatic Colorectal Cancer","status":"TERMINATED","sponsor":"Bristol-Myers Squibb","startDate":"2022-04-28","conditions":"Colorectal Neoplasms","enrollment":770},{"nctId":"NCT03642067","phase":"PHASE2","title":"Study of Nivolumab and Relatlimab in Patients With Microsatellite Stable (MSS) Advanced Colorectal Cancer","status":"COMPLETED","sponsor":"Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins","startDate":"2019-02-12","conditions":"Microsatellite Stable (MSS) Colorectal Adenocarcinomas, Colorectal Adenocarcinoma","enrollment":59},{"nctId":"NCT06101134","phase":"PHASE2","title":"A Study to Evaluate Whether Participants With Melanoma Prefer Subcutaneous vs Intravenous Administration of Nivolumab and Nivolumab + Relatlimab Fixed-dose Combinations","status":"ACTIVE_NOT_RECRUITING","sponsor":"Bristol-Myers Squibb","startDate":"2023-11-06","conditions":"Melanoma","enrollment":100},{"nctId":"NCT03459222","phase":"PHASE1, PHASE2","title":"An Investigational Study of Immunotherapy Combinations in Participants With Solid Cancers That Are Advanced or Have Spread","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2018-05-30","conditions":"Advanced Cancer","enrollment":229},{"nctId":"NCT02966548","phase":"PHASE1","title":"Safety Study of BMS-986016 With or Without Nivolumab in Patients With Advanced Solid Tumors","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2017-01-04","conditions":"Cancer","enrollment":35},{"nctId":"NCT03662659","phase":"PHASE2","title":"An Investigational Study of Immunotherapy Combinations With Chemotherapy in Patients With Gastric or Gastroesophageal Junction (GEJ) Cancers","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2018-10-16","conditions":"Gastric Cancer, Cancer of the Stomach, Esophagogastric Junction","enrollment":274},{"nctId":"NCT03743766","phase":"PHASE2","title":"Nivolumab, BMS-936558 in Combination with Relatlimab, BMS-986016 in Patients with Metastatic Melanoma Naïve to Prior Immunotherapy in the Metastatic Setting","status":"COMPLETED","sponsor":"John Kirkwood","startDate":"2019-03-29","conditions":"Melanoma","enrollment":42},{"nctId":"NCT06400264","phase":"PHASE2","title":"Testing Nivolumab and BMS-986016 (Relatlimab) as Potentially Targeting Treatment in Cancers That Are LAG-3+ and Have Mismatch Repair Deficiency (MATCH - Subprotocol Z1M)","status":"WITHDRAWN","sponsor":"National Cancer Institute (NCI)","startDate":"2022-02-22","conditions":"Advanced Lymphoma, Advanced Malignant Solid Neoplasm, Refractory Lymphoma","enrollment":""},{"nctId":"NCT03623854","phase":"PHASE2","title":"Nivolumab and Relatlimab in Treating Participants With Advanced Chordoma","status":"COMPLETED","sponsor":"Jonsson Comprehensive Cancer Center","startDate":"2019-04-03","conditions":"Chordoma, Locally Advanced Chordoma, Metastatic Chordoma","enrollment":10},{"nctId":"NCT05498480","phase":"PHASE1","title":"Study of Relatlimab in Combination With Nivolumab in Chinese Participants","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2022-07-27","conditions":"Advanced Solid Tumors","enrollment":6},{"nctId":"NCT02061761","phase":"PHASE1, PHASE2","title":"A Study to Evaluate the Safety, Tolerability, and Efficacy of Relatlimab in Relapsed or Refractory B-Cell Malignancies","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2014-03-13","conditions":"Hematologic Neoplasms","enrollment":106},{"nctId":"NCT05170685","phase":"","title":"Expanded Access for Fixed-Dose Combination of Nivolumab Plus Relatlimab","status":"NO_LONGER_AVAILABLE","sponsor":"Bristol-Myers Squibb","startDate":"","conditions":"","enrollment":""}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["BMS-986213"],"phase":"phase_3","status":"active","brandName":"Nivolumab-relatlimab FDC","genericName":"Nivolumab-relatlimab FDC","companyName":"Bristol-Myers Squibb","companyId":"bristol-myers-squibb","modality":"Small molecule","firstApprovalDate":"","aiSummary":"This fixed-dose combination blocks both PD-1 and LAG-3 checkpoints on immune cells, releasing dual brakes on anti-tumor immunity. Used for Melanoma (advanced or metastatic), Non-small cell lung cancer.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}